Want to see TLRY full AI Analyst Report?
Tilray (TLRY) Stock Price & Analysis
TLRY Stock Chart & Stats
- Day’s Range
- $2.75 - $2.94
- 52-Week Range
- $2.49 - $15.70
- Previous Close
- $2.81
- Volume
- N/A
- Average Volume (3M)
- 4.88M
- Market Cap
- $431.54M
- Enterprise Value
- $743.22M
- Total Cash (Recent Filing)
- $218.01M
- Total Debt (Recent Filing)
- $371.93M
- Price to Earnings (P/E)
- ―
- Beta
- 1.04
- Next Earnings
- Jan 11, 2027 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Global Platform
Tilray’s presence across cannabis, beverages, wellness and pharmaceutical distribution reduces reliance on a single category or market. Its operations in more than 25 countries provide multiple avenues for product expansion, channel development and geographic growth over the next several quarters.
Beverage Growth And Margin Expansion
Strong beverage growth alongside higher gross margins indicates that Tilray is gaining operating leverage in a significant non-cannabis segment. Improving category economics can support more durable earnings diversification, especially as brand distribution and product scale continue to develop.
International Medical Cannabis Growth
International medical cannabis growth demonstrates demand beyond Tilray’s mature Canadian market and supports the value of its European infrastructure. Rising patient demand in Germany and contributions from Lyphe can expand recurring distribution and patient-access opportunities over time.
Bears Say
Persistent Cash Burn
Negative operating and free cash flow means Tilray is not currently self-funding its operations, despite some improvement from the prior annual period. Continued cash burn can constrain investment flexibility and make sustained profitability, financing discipline and capital allocation more important.
Cannabis Revenue And Pricing Pressure
Cannabis remains a core business, yet revenue contraction and international price compression are limiting its contribution to growth and gross profit. Even with better reported margins, weaker volume or pricing can make earnings improvement less durable across upcoming quarters.
Challenging Legacy U.S. Beverage Market
Weakness in the legacy U.S. craft beverage portfolio shows that reported beverage growth is partly dependent on BrewDog’s contribution rather than broad-based category strength. SKU and brand rationalization may improve focus, but they also indicate ongoing pressure on the underlying business.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
What is Tilray’s market cap?
When is Tilray’s upcoming earnings report date?
How were Tilray’s earnings last quarter?
Is Tilray overvalued?
Does Tilray pay dividends?
What is Tilray’s EPS estimate?
How many shares outstanding does Tilray have?
What happened to Tilray’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tilray?
What is the TipRanks Smart Score and how is it calculated?
Tilray Stock Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Irwin David Simon
- Employees
- 3,595
- Website
- www.tilray.com
- Address
- 265 Talbot Street West, Leamington, ON, N8H 5L4, CA
Tilray (TLRY) Earnings & Revenues
TLRY Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Tilray reported record revenue and gross profit, expanding consolidated and cannabis margins, strong international cannabis and BrewDog growth, U.S. craft beer brand momentum, debt reduction, and reaffirmed fiscal 2027 adjusted EBITDA guidance. These strengths were partly offset by a $40 million net loss, lower adjusted EBITDA, total cannabis revenue contraction, international price compression, Canadian adult-use headwinds, fuel costs, higher investment costs, and continued regulatory and market uncertainty.
View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 5 | 0 | 7 |












